Abstract
INTRODUCTION
Controlled release solid dosage forms are available either as single unit or as multiple unit forms 1, 2 . A multiunit dosage form thus consists of particles (units) of differing release profiles with respect to onset, rate and the maximum release, etc. Controlled-release products are designed to decrease the dosing frequency and enhance patient compliance. In the last two decades, sustained -release dosage forms have made significant progress in terms of clinical efficacy and patient compliance 3 . Preparation of drug -embedded matrix tablets that involves the direct compression of a blend of drug and the matrix forming additives is one of the least complicated approaches for delivering drug in a controlled release pattern into the systemic circulation 4 . In an alternative approach, a combination of talc and magnesium stearate has been used to achieve zero -order release of ibuprofen from extended release tablets 5 . Talc is mainly used as a glidant and magnesium stearate as a lubricant in tablet formulations. Both materials are hydrophobic with a potential to repel water influx into tablets, hence retard drug release from such tablets. Previous studies 6, 7 have also shown that melt granulation (whereby the drug powder is triturated with a melted wax to form granules) is an effective means of retarding drug from drug particles. More recently, this technique has been used to retard the release of paracetamol from its melt granules using goat wax, carnuba wax and glyceryl monosterate in the melt granulation 8 . The purpose of the present study is to investigate how incorporation of hydrophobic agents (talc and magnesium stearate) will further modify the release profiles of the melt granules. The study thus sought for a simple approach for effectively modifying drug release from granules. Such granules could ultimately be encapsulated or tableted for multi-unit dose applications.
MATERIALS AND METHODS Materials
Carnuba wax (Halewood Chemicals Ltd, England) was used in the melt granulation. It is a fine waxy solid with melting point of 82-88 0 C, yellowish in colour. It was selected as material for coating because it is not sticky; hence it produces free flowing granules compared with other wax materials (i.e., goat fat and glyceryl monosterate). Talc (Get-Rid Pharm Pvt, Ltd, Pune, India) and magnesium stearate (BDH, Poole, UK). The test drug, paracetamol, was supplied by BDH (Poole, UK). Although sustained release formulations are usually applied to potent drugs with short biologic halflife, a readily available drug (paracetamol) was used to demonstrate the principle of retard release by melt granulation.
Methods

Melt granulation technique
Carnuba wax (20g) was melted in a stainless steel container in a water bath at a temperature higher than the melting point of the wax material (i.e., 90 0 C). Paracetamol and the hydrophobic material (i.e., talc or magnesium stearate powder) were blended in varying proportions (Table 1) . A sample of the paracetamol alone or the powder mixture (80g) was mixed with the melted wax in a Kenwood mixer (Model A901P England). The mass was pressed through a sieve of 710µm aperture size and dried in a vacuum oven (model A2904, Gallenkamp, England) at 25 0 C for 1h. Convectional granules of paracetamol were produced by wet massing a sample of the paracetamol powder (100g) with 20%w/v starch mucilage (38ml). The wet mass was screened and dried in a vacuum oven at 25 0 C for 1h. Moisture content of the resulting granules were 2.3±1.1%w/w (conventional granulation) and 2.1±1.5%w/w (melt granulation).
Dissolution test
Fines of size (< 210µm) were removed from the granules by sieving. A sample of the granules (500mg) was filled into a capsule shell and placed in a cylindrical basket (aperture size 425µm, diameter 20mm; height 30mm), which was immersed in 800ml of leaching fluid (0.1N hydrochloric acid maintained at 37 ± 2 o C). The fluid was stirred at 100rpm with a single blade GallenKamp stirrer (Model APP No 4B 5784A. Cat No: SS530). Samples (5ml) were withdrawn from the leaching fluid at selected time intervals with a pipette fitted with a cotton wool plug, replacing with an equal volume of drug-free dissolution fluid. The samples were suitably diluted with blank dissolution fluid and analysed for content of paracetamol spectrophotometrically at λ max , 245nm using Spectronic 21D, (Bausch and Lomb, USA). For the wax-coated granules, the samples were kept in the fridge overnight to allow solidification of the melted wax, which may have leached during the dissolution test. The samples were filtered before assay. The amounts released were expressed as a percentage of the initial amount of drug in the granule samples. The determination was carried out in triplicate and the mean results reported. Plots of amounts released (%) vs time were constructed. The release rates were obtained from the slopes of the linear portions of the plots. Other parameters obtained from the plots were the maximum release (m ∞ ) and the time to attain it (t ∞ ).
RESULTS
Effect of melt granulation on the release profiles of the drug particles
The effect of melt granulation on the release profiles of paracetamol is shown in Fig 1. The melt granulations displayed a retarded release compared with the conventional granules. For instance, with the convectional granules, maximal release was achieved in 3h and the dissolution rate was 32.3%h -1 . After melt granulation with the carnuba wax, maximal release was now achieved in 8h, with a dissolution rate of 11.6%h Content of HA 0%w/w (…♦…), 5%w/w (■), 10%w/w (▲), 20%w/w (△), 30%w/w ( ), 40%w/w (h), and 50%w/w (○).
